Berenberg cuts PolyPeptide as tender offer, share gains limit upside

PolyPeptide AG

18/08/2026 09:05

** Berenberg downgrades Swiss peptide manufacturer PolyPeptide PPGN.S to "hold" from "buy" as recent stock gains and an ongoing tender offer leave "little room for upside"
** The broker notes Samsung Biologics' 207940.KS offer to acquire all publicly held shares could accelerate the company's expansion but reduces the potential for near-term rerating
** Despite the downgrade, Berenberg remains confident in PolyPeptide's turnaround following strong H1 sales driven by demand for metabolic therapeutics
** It expects higher asset utilisation, efficiency gains and operating leverage to support long-term growth outlook
** Out of 7 analysts that cover PolyPeptide Group AG, three rate the stock "strong buy" or "buy,"​ two rate "hold" and two​ rate "strong sell" or "sell"  - SEG data

(Reporting by Orest Dovhan)
((Orest.Dovhan@thomsonreuters.com))